NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT00090051 2017-08-01
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Hoffmann-La Roche
Phase 3 Completed
NCT00086580 2014-03-13
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Sanofi
Phase 3 Completed
NCT00220311 2013-12-04
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
Sanofi
Phase 4 Completed
NCT00344825 2013-12-04
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
Sanofi
Completed
NCT00281918 2013-09-19
CLL-8
Hoffmann-La Roche
Phase 3 Completed